Agenus Inc Stock Today
| AGEN Stock | USD 2.86 0.19 7.12% |
Performance0 of 100
| Odds Of DistressOver 80
|
Agenus is selling at 2.86 as of the 21st of November 2024; that is 7.12 percent increase since the beginning of the trading day. The stock's open price was 2.67. Agenus has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Agenus Inc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of December 2022 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of February 2000 | Category Healthcare | Classification Health Care |
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Agenus operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 23.46 M outstanding shares of which 2.8 M shares are presently shorted by private and institutional investors with about 9.01 trading days to cover. More on Agenus Inc
Moving together with Agenus Stock
Moving against Agenus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Agenus Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Garo Armen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAgenus can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Agenus' financial leverage. It provides some insight into what part of Agenus' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Agenus Inc (AGEN) is traded on NASDAQ Exchange in USA. It is located in 3 Forbes Road, Lexington, MA, United States, 02421-7305 and employs 389 people. Agenus is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 62.64 M. Agenus Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 23.46 M outstanding shares of which 2.8 M shares are presently shorted by private and institutional investors with about 9.01 trading days to cover.
Agenus Inc currently holds about 218.23 M in cash with (224.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.72.
Check Agenus Probability Of Bankruptcy
Ownership AllocationAgenus holds a total of 23.46 Million outstanding shares. 30% of Agenus Inc outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Agenus Ownership Details
Agenus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Woodline Partners Lp | 2024-06-30 | 110.2 K | |
| Exoduspoint Capital Management, Lp | 2024-09-30 | 100.6 K | |
| Wellington Management Company Llp | 2024-06-30 | 92.4 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 89.6 K | |
| Fmr Inc | 2024-09-30 | 85.3 K | |
| Ubs O'connor Llc | 2024-06-30 | 75.2 K | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 72.2 K | |
| Key Client Fiduciary Advisors, Llc | 2024-09-30 | 67.4 K | |
| Susquehanna Fundamental Investments, Llc | 2024-06-30 | 62.7 K | |
| Vanguard Group Inc | 2024-09-30 | 2.3 M | |
| Blackrock Inc | 2024-06-30 | 1.5 M |
Agenus Historical Income Statement
Agenus Stock Against Markets
Agenus Corporate Management
| Julie DeSander | Chief Officer | Profile | |
| Alfred Dadson | Chief Officer | Profile | |
| Eric Humes | Chief Officer | Profile | |
| Regina Grebla | VP Communications | Profile | |
| Dr MBA | Chief Officer | Profile | |
| John Castle | Head Bioinformatics | Profile | |
| Zack Armen | Head Relations | Profile |
Already Invested in Agenus Inc?
The danger of trading Agenus Inc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Agenus is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Agenus. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Agenus Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Agenus Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agenus' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agenus Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agenus Inc Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agenus Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agenus. If investors know Agenus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agenus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.45) | Revenue Per Share 7.808 | Quarterly Revenue Growth 0.033 | Return On Assets (0.22) | Return On Equity (12.79) |
The market value of Agenus Inc is measured differently than its book value, which is the value of Agenus that is recorded on the company's balance sheet. Investors also form their own opinion of Agenus' value that differs from its market value or its book value, called intrinsic value, which is Agenus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agenus' market value can be influenced by many factors that don't directly affect Agenus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agenus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Agenus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agenus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.